ArticleSAGE open medical case reports2025
Low-dose isotretinoin for the treatment of Morbihan's disease in a 69-year-old Asian male: A case report.
Article in SAGE open medical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Morbihan's disease is a rare form of facial lymphedema often associated with chronic rosacea and other skin diseases such as acne. It presents as indurated erythematous plaques in the upper face, which can be challenging to treat. We report a 69-year-old male of Asian background with a 4-year history of facial swelling and redness, unresponsive to prior treatments. After a clinical diagnosis of Morbihan's disease, the patient was treated with oral isotretinoin 10 mg daily, leading to an 80% reduction in symptoms after 9 months. Mild side effects, including cheilitis and xerosis, were well managed. This case highlights low-dose isotretinoin's potential as a therapeutic option for Morbihan's disease. Previous studies have demonstrated the efficacy of treating Morbihan's disease with isotretinoin at high doses between 40 and 80 mg po daily for 12-24 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.